About Kopran Limited
Data last updated:
Kopran Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 26 April 1958 and has been in existence for over 68 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24230MH1958PLC011078. The company has 1 GST registration on record, which is no longer active. It is a listed company as per MCA records. Its shares are listed on BSE: 524280 and NSE: KOPRAN.
The company has an authorised share capital of ₹70 Cr and a paid-up capital of ₹48.29 Cr. It was formerly known as Kopran Chemical Company Private Limited. It is led by directors including Somani Surendra (Managing Director) and Mamta Ashok Biyani.
Its last annual general meeting (AGM) was held on 11 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Parijat House1076 Dr E Moses Road Worli Mumbai – 18, Maharashtra, India – 400018.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹681.42 Cr, a growth of 8.2% compared to the previous year. For the same year it recorded a net profit of ₹25.73 Cr (net margin 3.8%) and EBITDA of ₹61.95 Cr (EBITDA margin 9.1%). The net worth stands at ₹530.28 Cr (up 2.3% YoY). Total assets are valued at ₹691.91 Cr (up 2.2% YoY).
The company has about 363 employees on its provident fund (EPFO) records. Its group structure includes 2 subsidiaries.
The company is associated with 1 brand: Kopran. As per MCA filings, the company has open charges of ₹831.16 Cr and satisfied charges of ₹752.55 Cr on record. Court records list 227 cases involving the company, including 93 filed by the company and 139 filed against it; 24 cases are pending. The company has 121 deals on record (116 market trades, 2 funding rounds, 2 secondary share transfers), with disclosed funding of ₹184.41 Cr; the latest was in September 2026. Its 8 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 4 smaller; the largest is Tablets (India) Ltd with revenue of ₹667.39 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website kopran.com.
Company details
Contact details
Kopran Limited's registered office is in Mumbai, Maharashtra. Its website is kopran.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressParijat House1076 Dr E Moses Road Worli Mumbai – 18, Maharashtra, India – 400018
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Kopran Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Kopran operates one associated brand: Kopran. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical Company manufacturing a range of products | kopran.com |
Business activity
The main business activity of Kopran is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Kopran Limited, buy the company report.
Financials of Kopran Limited
FY 2025-26 filings availableKopran Limited reported revenue of ₹681.42 Cr (up 8.2% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 681 | 630 | 615 | 551 | 478 | 492 | 360 |
| Revenue growth | +8.2% | +2.4% | +11.5% | +15.4% | -2.9% | +36.8% | - |
| EBITDA | 61.95 | 72.88 | 74.41 | 51.79 | 87.38 | 81.77 | 46.14 |
| EBITDA margin | +9.1% | +11.6% | +12.1% | +9.4% | +18.3% | +16.6% | +12.8% |
| Profit before tax | 34.36 | 51.93 | 67.54 | 36.07 | 81.76 | 83.33 | 28.28 |
| Net profit | 25.73 | 38.54 | 50.95 | 27.24 | 61.01 | 61.69 | 21.50 |
| Net profit margin | +3.8% | +6.1% | +8.3% | +4.9% | +12.8% | +12.5% | +6.0% |
| EPS (₹) | 5.33 | 7.98 | 10.57 | 5.65 | 12.66 | 14.24 | 4.86 |
| Balance sheet | |||||||
| Total assets | 692 | 677 | 599 | 523 | 509 | 319 | 285 |
| Net worth | 530 | 518 | 491 | 439 | 426 | 245 | 190 |
| Total debt | 153 | 148 | 99.23 | 75.24 | 74.55 | 66.31 | 88.28 |
| Cash & bank | 7.22 | 25.86 | 14.20 | 12.58 | 57.13 | 6.90 | 4.75 |
| Net working capital | 316 | 352 | 318 | 279 | 319 | 161 | 139 |
| Cash flow | |||||||
| Cash from operations | 66.75 | 41.94 | 43.26 | 34.02 | (33.48) | 59.95 | 31.00 |
| Cash from investing | (64.60) | (56.43) | (43.55) | (12.65) | (84.42) | (25.28) | (12.52) |
| Cash from financing | (20.94) | 25.87 | 0.99 | (19.84) | 123 | (34.57) | (18.06) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 154 | 234 | 194 | 118 | 135 | 172 | 166 | 152 |
| Revenue growth (YoY) | +13.9% | +35.8% | +16.9% | -22.2% | -3.0% | - | - | - |
| Other income | 2.05 | 0.09 | 0.07 | 0.03 | 2.56 | 3.26 | 0.17 | 1.00 |
| EBITDA | 15.80 | 32.95 | 17.76 | (5.28) | 14.13 | 17.08 | 19.84 | 14.74 |
| EBITDA margin | +10.3% | +14.1% | +9.1% | -4.5% | +10.4% | +9.9% | +11.9% | +9.7% |
| Depreciation | 5.77 | 4.52 | 4.42 | 4.28 | 4.26 | 3.87 | 4.00 | 3.85 |
| Interest | 3.28 | 3.17 | 2.67 | 2.09 | 2.54 | 2.77 | 2.16 | 2.23 |
| Profit before tax | 8.80 | 25.35 | 10.74 | (11.62) | 9.89 | 13.70 | 13.85 | 9.66 |
| Tax | 2.10 | 6.48 | 1.40 | (1.70) | 2.44 | 4.03 | 3.46 | 2.26 |
| Net profit | 6.70 | 18.87 | 9.34 | (9.92) | 7.45 | 9.67 | 10.39 | 7.40 |
| EPS (₹) | 1.39 | 3.91 | 1.93 | (2.06) | 1.54 | 2.00 | 2.15 | 1.53 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 306 | 271 | 337 | 273 | 205 | 223 | 179 |
| Revenue growth | +12.8% | -19.7% | +23.6% | +33.5% | -8.2% | +24.3% | - |
| EBITDA | 47.57 | 38.65 | 36.93 | 27.90 | 15.43 | 30.20 | 23.17 |
| EBITDA margin | +15.6% | +14.3% | +10.9% | +10.2% | +7.5% | +13.6% | +12.9% |
| Profit before tax | 40.39 | 35.78 | 44.52 | 36.91 | 16.19 | 32.70 | 15.73 |
| Net profit | 30.39 | 26.84 | 34.65 | 31.25 | 11.77 | 23.47 | 11.26 |
| Net profit margin | +9.9% | +9.9% | +10.3% | +11.4% | +5.8% | +10.5% | +6.3% |
| EPS (₹) | 6.30 | 5.56 | 7.18 | 6.48 | 2.44 | 5.43 | 2.59 |
| Balance sheet | |||||||
| Total assets | 498 | 482 | 444 | 428 | 420 | 266 | 279 |
| Net worth | 448 | 431 | 417 | 396 | 379 | 247 | 230 |
| Total debt | 46.36 | 45.31 | 22.71 | 27.88 | 36.90 | 15.72 | 45.72 |
| Cash & bank | 2.18 | 21.02 | 7.42 | 2.59 | 2.55 | 3.22 | 1.15 |
| Net working capital | 137 | 147 | 124 | 115 | 110 | 55.88 | 66.42 |
| Cash flow | |||||||
| Cash from operations | 29.66 | 23.30 | 34.96 | 16.87 | (37.80) | 48.77 | 9.97 |
| Cash from investing | (30.08) | (15.41) | (6.27) | 10.05 | (100) | (8.51) | 0.63 |
| Cash from financing | (18.53) | 5.64 | (24.08) | (26.13) | 138 | (40.14) | (10.60) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 62.76 | 118 | 93.88 | 42.39 | 51.33 | 75.94 | 71.94 | 73.53 |
| Revenue growth (YoY) | +22.3% | +55.4% | +30.5% | -42.4% | +3.5% | - | - | - |
| Other income | 2.91 | 1.00 | 0.32 | 0.32 | 1.80 | 1.92 | 0.75 | 1.12 |
| Total expenses | 54.30 | 91.45 | 76.20 | 45.60 | 46.26 | 63.65 | 60.54 | 63.84 |
| EBITDA | 8.46 | 26.59 | 17.68 | (3.21) | 5.07 | 12.29 | 11.40 | 9.69 |
| EBITDA margin | +13.5% | +22.5% | +18.8% | -7.6% | +9.9% | +16.2% | +15.8% | +13.2% |
| Depreciation | 1.35 | 1.34 | 1.25 | 1.16 | 1.22 | 1.24 | 1.33 | 1.23 |
| Interest | 1.24 | 1.17 | 1.16 | 0.83 | 1.04 | 1.26 | 0.99 | 0.83 |
| Profit before tax | 8.78 | 25.08 | 15.59 | (4.88) | 4.61 | 11.71 | 9.83 | 8.75 |
| Tax | 2.06 | 6.33 | 3.45 | (0.88) | 1.09 | 3.11 | 2.42 | 2.15 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 154 | 234 | 194 | 118 | 135 | 172 | 166 | 152 |
| Revenue growth (YoY) | +13.9% | +35.8% | +16.9% | -22.2% | -3.0% | - | - | - |
| Other income | 2.05 | 0.09 | 0.07 | 0.03 | 2.56 | 3.26 | 0.17 | 1.00 |
| EBITDA | 15.80 | 32.95 | 17.76 | (5.28) | 14.13 | 17.08 | 19.84 | 14.74 |
| EBITDA margin | +10.3% | +14.1% | +9.1% | -4.5% | +10.4% | +9.9% | +11.9% | +9.7% |
| Depreciation | 5.77 | 4.52 | 4.42 | 4.28 | 4.26 | 3.87 | 4.00 | 3.85 |
| Interest | 3.28 | 3.17 | 2.67 | 2.09 | 2.54 | 2.77 | 2.16 | 2.23 |
| Profit before tax | 8.80 | 25.35 | 10.74 | (11.62) | 9.89 | 13.70 | 13.85 | 9.66 |
| Tax | 2.10 | 6.48 | 1.40 | (1.70) | 2.44 | 4.03 | 3.46 | 2.26 |
| Net profit | 6.70 | 18.87 | 9.34 | (9.92) | 7.45 | 9.67 | 10.39 | 7.40 |
| EPS (₹) | 1.39 | 3.91 | 1.93 | (2.06) | 1.54 | 2.00 | 2.15 | 1.53 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 681 | 630 | 615 | 551 | 478 | 492 | 360 |
| Revenue growth | +8.2% | +2.4% | +11.5% | +15.4% | -2.9% | +36.8% | - |
| Other income | 0.35 | 3.98 | 14.61 | 3.07 | 10.60 | 17.99 | 0.63 |
| Total expenses | 619 | 557 | 540 | 499 | 390 | 410 | 313 |
| Employee cost | 65.21 | 60.54 | 52.28 | 49.95 | 43.27 | 37.16 | 36.85 |
| EBITDA | 61.95 | 72.88 | 74.41 | 51.79 | 87.38 | 81.77 | 46.14 |
| EBITDA margin | +9.1% | +11.6% | +12.1% | +9.4% | +18.3% | +16.6% | +12.8% |
| Depreciation | 17.47 | 15.59 | 12.89 | 12.71 | 11.10 | 10.19 | 9.58 |
| Interest | 10.47 | 9.34 | 8.59 | 6.08 | 5.12 | 6.24 | 8.91 |
| Profit before tax | 34.36 | 51.93 | 67.54 | 36.07 | 81.76 | 83.33 | 28.28 |
| Tax | 8.63 | 13.39 | 16.59 | 8.83 | 20.75 | 21.73 | 7.27 |
| Net profit | 25.73 | 38.54 | 50.95 | 27.24 | 61.01 | 61.69 | 21.50 |
| Net profit margin | +3.8% | +6.1% | +8.3% | +4.9% | +12.8% | +12.5% | +6.0% |
| EPS (₹) | 5.33 | 7.98 | 10.57 | 5.65 | 12.66 | 14.24 | 4.86 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 48.29 | 48.29 | 48.21 | 48.21 | 48.21 | 43.25 | 43.25 |
| Reserves & surplus | 482 | 470 | 443 | 391 | 378 | 202 | 146 |
| Shareholders' funds (net worth) | 530 | 518 | 491 | 439 | 426 | 245 | 190 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 130 | 133 | 83.05 | 57.98 | 55.64 | 61.33 | 62.88 |
| Unsecured loans | 22.72 | 14.47 | 16.18 | 17.26 | 18.91 | 4.98 | 25.40 |
| Total debt | 153 | 148 | 99.23 | 75.24 | 74.55 | 66.31 | 88.28 |
| Total liabilities | 692 | 677 | 599 | 523 | 509 | 319 | 285 |
| Assets | |||||||
| Gross block | 461 | 306 | 263 | 234 | 207 | 157 | 146 |
| Net block | 346 | 208 | 182 | 165 | 151 | 112 | 111 |
| Capital work in progress | 24.79 | 113 | 96.59 | 69.58 | 35.55 | 42.89 | 30.24 |
| Investments | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.05 | 0.02 |
| Inventories | 164 | 169 | 138 | 131 | 150 | 100 | 88.50 |
| Sundry debtors | 263 | 215 | 212 | 163 | 127 | 120 | 92.81 |
| Cash & bank balances | 7.22 | 25.86 | 14.20 | 12.58 | 57.13 | 6.90 | 4.75 |
| Loans & advances | 89.09 | 99.53 | 89.02 | 93.32 | 80.44 | 49.97 | 36.55 |
| Total current assets | 523 | 510 | 454 | 399 | 415 | 277 | 223 |
| Total current liabilities | 207 | 158 | 136 | 120 | 95.80 | 116 | 83.61 |
| Net working capital | 316 | 352 | 318 | 279 | 319 | 161 | 139 |
| Total assets | 692 | 677 | 599 | 523 | 509 | 319 | 285 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 19.47 | 8.09 | 7.40 | 5.87 | 0.94 | 0.83 | 0.41 |
| Net cash from operating activities | 66.75 | 41.94 | 43.26 | 34.02 | (33.48) | 59.95 | 31.00 |
| Net cash from investing activities | (64.60) | (56.43) | (43.55) | (12.65) | (84.42) | (25.28) | (12.52) |
| Net cash from financing activities | (20.94) | 25.87 | 0.99 | (19.84) | 123 | (34.57) | (18.06) |
| Net change in cash | (18.79) | 11.38 | 0.69 | 1.53 | 4.93 | 0.10 | 0.42 |
| Closing cash | 7.22 | 25.86 | 14.20 | 12.58 | 57.13 | 6.90 | 4.75 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +8.2% | +2.4% | +11.5% | +15.4% | -2.9% | +36.8% | - |
| EBITDA growth | -15.0% | -2.1% | +43.7% | -40.7% | +6.9% | +77.2% | - |
| PBT growth | -33.8% | -23.1% | +87.3% | -55.9% | -1.9% | +194.7% | -10.7% |
| Net income growth | -33.2% | -24.4% | +87.0% | -55.4% | -1.1% | +186.9% | - |
| Revenue CAGR (3Y) | +7.3% | +9.7% | +7.7% | +15.3% | +10.1% | +16.2% | +5.1% |
| EBITDA CAGR (3Y) | +6.2% | -5.9% | -3.1% | +3.9% | +23.6% | +39.1% | +8.6% |
| Profitability & leverage | |||||||
| Net income margin | +3.8% | +6.1% | +8.3% | +4.9% | +12.8% | +12.5% | +5.8% |
| Return on capital employed | +6.6% | +9.6% | +13.6% | +8.2% | +21.0% | +29.6% | +12.8% |
| Return on net worth | +4.9% | +7.6% | +11.0% | +6.3% | +18.2% | +28.3% | +11.1% |
| Debt / equity | 0.29 | 0.24 | 0.19 | 0.17 | 0.21 | 0.36 | 0.49 |
| Long-term debt / equity | 0.03 | 0.03 | 0.03 | 0.04 | 0.05 | 0.11 | 0.16 |
| Interest cover | 23.54 | 16.30 | 13.96 | 15.56 | 6.71 | 8.72 | 24.37 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.78 | 2.21 | 2.47 | 2.50 | 2.62 | 3.24 | 2.53 |
| Inventory turnover | 4.08 | 4.09 | 4.57 | 3.93 | 3.82 | 5.22 | 4.44 |
| Debtors turnover | 2.85 | 2.95 | 3.28 | 3.80 | 3.86 | 4.62 | 4.01 |
| EPS (₹) | 5.33 | 7.98 | 10.57 | 5.65 | 12.66 | 14.24 | 4.86 |
| Dividend per share (₹) | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 0.00 |
| Book value per share (₹) | 109.82 | 107.35 | 101.90 | 91.11 | 88.40 | 56.65 | 43.86 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 62.76 | 118 | 93.88 | 42.39 | 51.33 | 75.94 | 71.94 | 73.53 |
| Revenue growth (YoY) | +22.3% | +55.4% | +30.5% | -42.4% | +3.5% | - | - | - |
| Other income | 2.91 | 1.00 | 0.32 | 0.32 | 1.80 | 1.92 | 0.75 | 1.12 |
| Total expenses | 54.30 | 91.45 | 76.20 | 45.60 | 46.26 | 63.65 | 60.54 | 63.84 |
| EBITDA | 8.46 | 26.59 | 17.68 | (3.21) | 5.07 | 12.29 | 11.40 | 9.69 |
| EBITDA margin | +13.5% | +22.5% | +18.8% | -7.6% | +9.9% | +16.2% | +15.8% | +13.2% |
| Depreciation | 1.35 | 1.34 | 1.25 | 1.16 | 1.22 | 1.24 | 1.33 | 1.23 |
| Interest | 1.24 | 1.17 | 1.16 | 0.83 | 1.04 | 1.26 | 0.99 | 0.83 |
| Profit before tax | 8.78 | 25.08 | 15.59 | (4.88) | 4.61 | 11.71 | 9.83 | 8.75 |
| Tax | 2.06 | 6.33 | 3.45 | (0.88) | 1.09 | 3.11 | 2.42 | 2.15 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 306 | 271 | 337 | 273 | 205 | 223 | 179 |
| Revenue growth | +12.8% | -19.7% | +23.6% | +33.5% | -8.2% | +24.3% | - |
| Other income | 2.00 | 5.90 | 16.71 | 16.09 | 8.03 | 10.41 | 1.99 |
| Total expenses | 258 | 232 | 301 | 245 | 189 | 193 | 156 |
| Employee cost | 32.94 | 30.02 | 25.61 | 25.15 | 21.05 | 18.34 | 20.02 |
| EBITDA | 47.57 | 38.65 | 36.93 | 27.90 | 15.43 | 30.20 | 23.17 |
| EBITDA margin | +15.6% | +14.3% | +10.9% | +10.2% | +7.5% | +13.6% | +12.9% |
| Depreciation | 4.98 | 5.00 | 4.62 | 4.41 | 4.32 | 4.10 | 3.47 |
| Interest | 4.20 | 3.77 | 4.50 | 2.67 | 2.95 | 3.81 | 5.96 |
| Profit before tax | 40.39 | 35.78 | 44.52 | 36.91 | 16.19 | 32.70 | 15.73 |
| Tax | 10.00 | 8.94 | 9.88 | 5.66 | 4.42 | 9.24 | 4.51 |
| Net profit | 30.39 | 26.84 | 34.65 | 31.25 | 11.77 | 23.47 | 11.26 |
| Net profit margin | +9.9% | +9.9% | +10.3% | +11.4% | +5.8% | +10.5% | +6.3% |
| EPS (₹) | 6.30 | 5.56 | 7.18 | 6.48 | 2.44 | 5.43 | 2.59 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 48.29 | 48.29 | 48.21 | 48.21 | 48.21 | 43.25 | 43.25 |
| Reserves & surplus | 400 | 383 | 369 | 347 | 331 | 204 | 186 |
| Shareholders' funds (net worth) | 448 | 431 | 417 | 396 | 379 | 247 | 230 |
| Secured loans | 44.36 | 43.31 | 20.71 | 25.88 | 26.82 | 12.72 | 14.40 |
| Unsecured loans | 2.00 | 2.00 | 2.00 | 2.00 | 10.08 | 3.00 | 31.32 |
| Total debt | 46.36 | 45.31 | 22.71 | 27.88 | 36.90 | 15.72 | 45.72 |
| Total liabilities | 498 | 482 | 444 | 428 | 420 | 266 | 279 |
| Assets | |||||||
| Gross block | 122 | 96.67 | 82.46 | 73.17 | 67.63 | 64.60 | 56.00 |
| Net block | 81.88 | 61.45 | 52.02 | 47.35 | 46.22 | 47.44 | 42.95 |
| Capital work in progress | 7.59 | 7.44 | 4.70 | 3.53 | 3.10 | 2.82 | 7.07 |
| Investments | 265 | 263 | 261 | 260 | 259 | 159 | 158 |
| Inventories | 65.85 | 55.75 | 49.49 | 47.60 | 41.51 | 27.50 | 41.17 |
| Sundry debtors | 133 | 91.92 | 87.80 | 83.81 | 59.13 | 49.46 | 42.48 |
| Cash & bank balances | 2.18 | 21.02 | 7.42 | 2.59 | 2.55 | 3.22 | 1.15 |
| Loans & advances | 39.64 | 40.36 | 42.99 | 56.40 | 48.11 | 30.92 | 29.44 |
| Total current assets | 240 | 209 | 188 | 190 | 151 | 111 | 114 |
| Total current liabilities | 104 | 61.57 | 64.06 | 75.29 | 41.43 | 55.22 | 47.82 |
| Net working capital | 137 | 147 | 124 | 115 | 110 | 55.88 | 66.42 |
| Total assets | 498 | 482 | 444 | 428 | 420 | 266 | 279 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 19.18 | 5.65 | 1.04 | 0.25 | 0.32 | 0.21 | 0.21 |
| Net cash from operating activities | 29.66 | 23.30 | 34.96 | 16.87 | (37.80) | 48.77 | 9.97 |
| Net cash from investing activities | (30.08) | (15.41) | (6.27) | 10.05 | (100) | (8.51) | 0.63 |
| Net cash from financing activities | (18.53) | 5.64 | (24.08) | (26.13) | 138 | (40.14) | (10.60) |
| Net change in cash | (18.95) | 13.53 | 4.61 | 0.79 | (0.07) | 0.12 | 0.00 |
| Closing cash | 2.18 | 21.02 | 7.42 | 2.59 | 2.55 | 3.22 | 1.15 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +12.8% | -19.7% | +23.6% | +33.5% | -8.2% | +24.3% | - |
| EBITDA growth | +23.1% | +4.7% | +32.4% | +80.8% | -48.9% | +30.3% | - |
| PBT growth | +12.9% | -19.6% | +20.6% | +128.0% | -50.5% | +107.9% | -9.4% |
| Net income growth | +13.2% | -22.5% | +10.9% | +165.5% | -49.9% | +108.4% | - |
| Revenue CAGR (3Y) | +3.8% | +9.8% | +14.8% | +15.1% | +1.3% | +13.2% | -0.4% |
| EBITDA CAGR (3Y) | +19.5% | +35.8% | +6.9% | +6.4% | -12.2% | +49.9% | +10.1% |
| Profitability & leverage | |||||||
| Net income margin | +9.9% | +9.9% | +10.3% | +11.4% | +5.8% | +10.5% | +6.3% |
| Return on capital employed | +9.1% | +8.5% | +11.2% | +9.3% | +5.6% | +13.4% | +7.9% |
| Return on net worth | +6.9% | +6.3% | +8.5% | +8.1% | +3.8% | +9.9% | +5.0% |
| Debt / equity | 0.10 | 0.08 | 0.06 | 0.08 | 0.08 | 0.13 | 0.20 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.04 |
| Interest cover | 9.86 | 11.20 | 13.93 | 11.37 | 26.55 | 14.60 | 30.25 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 2.80 | 3.03 | 4.34 | 3.88 | 3.09 | 3.70 | 3.34 |
| Inventory turnover | 5.03 | 5.15 | 6.95 | 6.13 | 5.93 | 6.49 | 5.40 |
| Debtors turnover | 2.72 | 3.02 | 3.93 | 3.82 | 3.77 | 4.85 | 4.12 |
| EPS (₹) | 6.30 | 5.56 | 7.18 | 6.48 | 2.44 | 5.43 | 2.59 |
| Dividend per share (₹) | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 0.00 |
| Book value per share (₹) | 92.75 | 89.35 | 86.47 | 82.05 | 78.56 | 57.07 | 53.10 |
To see the full year-wise statements and ratios of Kopran Limited, buy the company report.
Board of directors of Kopran Limited
Kopran has 6 current directors and 19 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Mamta Ashok Biyani Also directs: Image Commercials LLP, Damodar Industries Limited, Oricon Enterprises Limited and 3 more | Director | 08 May 2019 | 7 Years 5 Months | Current |
| Narayan Tulsiram Atal Also directs: International Conveyors Limited, Taparia Tools Limited, Gama Leafin Private Limited and 4 more | Director | 08 May 2019 | 7 Years 5 Months | Current |
| Somani Surendra Also directs: Kopran Lifesciences Limited | Managing Director | 11 Jun 1997 | 29 Years 4 Months | Current |
| Varun Surendra Somani Also directs: G Claridge and Company Limited, Kopran Laboratories Limited, Sorabh Trading Private Limited and 5 more | Director | 29 May 2018 | 8 Years 5 Months | Current |
| Chandresh Gunvant Gandhi Also directs: Control Print Limited | Director | 29 Jul 2025 | 1 Years 3 Months | Current |
| Namrata Varun Somani Also directs: Kopran Laboratories Limited, Sorabh Trading Private Limited, Apurva Caplease and Finance Private Limited and 3 more | Additional Director | 19 May 2026 | 0 Years 5 Months | Current |
Peer comparison
Kopran Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Kopran Limitedthis company | ₹681.42 Cr (FY 2026) | ₹25.73 Cr | 3.8% | 8.2% | 363 | Mumbai, Maharashtra, India |
| Tablets (India) Ltd | ₹667.39 Cr (FY 2025) | 9.0% | Chennai, Tamil Nadu, India | |||
| RPG Life Sciences Limited | ₹666.11 Cr (FY 2025) | 13.0% | Mumbai, Maharashtra, India | |||
| Lincoln Pharmaceuticals Ltd | ₹645.71 Cr (FY 2025) | 5.0% | Ahmedabad, Gujarat, India | |||
| Theon Pharmaceuticals Limited | ₹633.1 Cr (FY 2025) | 4.0% | Chandigarh, India | |||
| Samarth Life Sciences Private Limited | ₹624.79 Cr (FY 2025) | 11.0% | Mumbai, Maharashtra, India | |||
| Ra Chem Pharma Limited | ₹621.32 Cr (FY 2021) | 15.0% | Hyderabad, Telangana, India | |||
| Inventia Healthcare Limited | ₹620.73 Cr (FY 2025) | -19.0% | Mumbai, Maharashtra, India | |||
| Sri Krishna Pharmaceuticals Limited | ₹608.24 Cr (FY 2025) | -13.0% | Telangana, India |
To see the full peer comparison of Kopran Limited, buy the company report.
Auditor
Kopran Limited is audited by KHANDELWAL JAIN & CO. for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| KHANDELWAL JAIN & CO. | FY 2023 | 105049W |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 44.40%, foreign institutional investors hold 0.50%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 55.10%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 44.40% | 44.40% | 44.40% | 44.40% |
| Public | 55.60% | 55.60% | 55.60% | 55.60% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 30 Jul 2020 | 100360407 | State Bank of India | ₹124.75 Cr | Open | |
| 26 Dec 2014 | 10544136 | State Bank of India | ₹3.5 Cr | Open | |
| 28 Jan 2013 | 10406606 | State Bank of India | ₹11.5 Cr | Open | |
| 04 Jul 2007 | 10058570 | Canara Bank | ₹8 Cr | Open | |
| 10 Aug 2005 | 90243976 | State Bank of India | ₹2.6 Cr | Open |
To see the full charge records of Kopran Limited, buy the company report.
Total charge records: 108 View all charges
Deals & funding
Kopran Limited has 121 deals on record (116 market trades, 2 funding rounds, 2 secondary share transfers), with disclosed funding of ₹184.41 Cr; the latest was in September 2026.
Deals on record (5 of 121)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2026 | Market trade | ₹16.4 Cr | Seller: United Shippers Limited |
| May 2026 | Market trade | ₹13.29 Cr | Buyer: Yuga Stocks & Commodities Private Limited Seller: Yuga Stocks & Commodities Private Limited |
| May 2026 | Market trade | ₹8.02 Cr | Buyer: Yuga Stocks & Commodities Private Limited Seller: Yuga Stocks & Commodities Private Limited |
| May 2026 | Market trade | ₹81.67 Cr | Buyer: Yuga Stocks & Commodities Private Limited , Neo Apex Share Broking Services LLP , Setu Securities Private Limited Seller: Yuga Stocks & Commodities Private Limited , Neo Apex Share Broking Services LLP , Setu Securities Private Limited |
| May 2026 | Market trade | ₹5.66 Cr | Buyer: NK Securities Research Private Limited Seller: NK Securities Research Private Limited |
To see the full deal history of Kopran Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Kopran Limited has 227 court cases on record: 93 filed by Kopran, 139 filed against it. 24 cases are pending and 203 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 117 | 65 | 17 |
| District courts | 100 | 68 | 6 |
| Supreme Court | 9 | 5 | 0 |
| NCLAT | 1 | 1 | 1 |
Cases on record (5 of 227)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, HASSAN, Karnataka | Court case (Com.EX.) | Filed against the company by Ultra Laboratories Pvt Ltd., Rep. by Assistant Manager , Vijay Kumar C.D. | Pending |
| Bombay High Court | Interim or miscellaneous application | Filed against the company by Unimark Remedies Ltd | Pending |
| District court, Mumbai CMM Courts, Maharashtra | Interim or miscellaneous application | Filed by the company against Classic Credit Ltd and 2 Ors and 2 others | Pending |
| District court, HASSAN, Karnataka | Court case (Com.EX.) | Filed against the company by Ultra Laboratories Pvt Ltd., Rep. by Vijay Kumar C.D. | Disposed |
| Bombay High Court | Writ petition | Filed by the company against M/S Adore Pharmaceuticals Pvt. Ltd and 1 other | Disposed |
To see the full case history of Kopran Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Kopran Limited was last rated by Crisil on 07 Oct 2020.
| Rating agency | Rated on | Rating |
|---|---|---|
| Crisil | 07 Oct 2020 |
To see the full credit ratings and regulatory alerts of Kopran Limited, buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Kopran Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Group structure & subsidiaries
Kopran has 2 subsidiary companies. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares held |
|---|---|---|
| Kopran Research Laboratories Limited | U24230MH1986PLC040601 | |
| Kopran Lifesciences Limited | U74120MH2010PLC211125 |
To see the full group structure of Kopran Limited, buy the company report.
Employees & EPFO
Kopran Limited has a workforce of 363 employees on its EPFO records as of Apr 02, 2024, across 1 active EPFO establishment.
GST
Kopran has 1 GST registration on record, and it has been cancelled or is inactive. Only active GST numbers are listed on this page.
To see the full GST registrations and return filing status of Kopran Limited, buy the company report.
Recent activity
Kopran Limited has 34 board changes on record since 1982: 21 appointments and 13 cessations. The latest: Namrata Varun Somani was appointed as Additional Director on 19 May 2026.
237 earlier events are in the company report.
News
Frequently asked questions
Kopran is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 26 April 1958 (68+ years old) and is registered under CIN L24230MH1958PLC011078. Listed on BSE: 524280 and NSE: KOPRAN.
Kopran reported revenue of ₹681.42 Cr for FY 2025-26 (up 8.2% YoY) based on consolidated financials.
Kopran has 6 current directors:
- Somani Surendra - Managing Director
- Mamta Ashok Biyani - Director
- Narayan Tulsiram Atal - Director
- Varun Surendra Somani - Director
- Chandresh Gunvant Gandhi - Director
- Namrata Varun Somani - Additional Director
The latest financial statements of Kopran on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 11 September 2025. Year-wise statements from 2015 are in the company report.
No. Kopran has 1 GST registration on record and it is cancelled or inactive.
The CIN (Corporate Identification Number) of Kopran is L24230MH1958PLC011078. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Kopran is a listed company as per MCA records. Its shares are listed on both BSE (code: 524280) and NSE (symbol: KOPRAN).
Kopran has 227 court cases on record: 93 filed by the company and 139 filed against it. 24 are pending. Most are in the high courts.
Kopran was incorporated on 26 April 1958, making it 68+ years old. It is registered with the Registrar of Companies, Mumbai.
Kopran has 121 deals on record (116 market trades, 2 funding rounds, 2 secondary share transfers), with disclosed funding of ₹184.41 Cr; the latest was in September 2026.
The peers of Kopran by revenue are Tablets (India) Ltd, RPG Life Sciences Limited, Lincoln Pharmaceuticals Ltd, Theon Pharmaceuticals Limited, Samarth Life Sciences Private Limited and 3 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).